Unveiling the Mysteries of Clopidogrel Metabolism and Efficacy

Clopidogrel is an important antiplatelet agent, but a considerable variability in the biological effect of the drug has been observed. Additionally, patients with insufficient platelet reactivity inhibition following a loading dose (LD) of clopidogrel have a poor outcome. The mechanisms of variabili...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2011-12, Vol.90 (6), p.774-776
Main Authors: Bonello, L, Bonello, N, Grosdidier, C, Camoin‐Jau, L
Format: Article
Language:English
Subjects:
Aryldialkylphosphatase - genetics
Cardiovascular Diseases - genetics
Cardiovascular Diseases - mortality
Female
Genetic Association Studies - methods
Genetic Variation - genetics
Humans
Male
Myocardial Infarction - drug therapy
Myocardial Infarction - genetics
Polymorphism, Genetic - genetics
Ticlopidine - analogs & derivatives
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clopidogrel is an important antiplatelet agent, but a considerable variability in the biological effect of the drug has been observed. Additionally, patients with insufficient platelet reactivity inhibition following a loading dose (LD) of clopidogrel have a poor outcome. The mechanisms of variability are dependent on genetic polymorphisms of enzymes involved in clopidogrel metabolism. Paraoxonase 1 has been identified as the main determinant of the biological and clinical efficacy of clopidogrel. This finding could enable the use of pharmacogenomics to tailor antiplatelet agents. Clinical Pharmacology & Therapeutics (2011); 90 6, 774–776. doi:10.1038/clpt.2011.222
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2011.222